Bristol Myers Squibb Company Overview

In March 2016, the company announced that it would acquire Padlock Therapeutics for up to $600 million. [59] In early July, the Company announced that it would acquire Cormorant Pharmaceuticals for $520 million, strengthening the oncology offering of BMS with monoclonal antibody cormorants against interleukin-8. [60] In August 2017, the company acquired IFM Therapeutics for $300 million in advance, with $1.01 billion in milestone success payments due to help BMS better compete with keytruda, Merck & Co`s cancer competitor. [61] In December 2014, the company received FDA approval for the use of the inhibitor-1 nivolumab (Opdivo) in the treatment of patients whose skin cancer cannot be removed or has not responded to previous drug treatments. [45] In February 2015, the company entered into a research partnership with Rigel Pharmaceuticals that could generate more than $339 million. In March, the company had the exclusive opportunity to license and commercialize PROSTVAC, Bavarian Nordic`s prostate-specific Phase III antigen for cancer immunotherapy. Bavarian Nordic would receive an upfront payment of $60 million, as well as additional payments of up to $230 million if the overall survival of the patients tested exceeds that observed in the Phase II trials. Bavaria could also receive milestone payments of between $110 million and $495 million, subject to regulatory approval, and these payments can reach $975 million. In 1887, William McLaren Bristol and John Ripley Myers, graduates of Hamilton College, purchased the Clinton Pharmaceutical Company in Clinton, New York.[46] In May 1898 they decided to rename it Bristol, Myers and Company.[18] After Myers` death in 1899, Bristol changed its name to Bristol-Myers Corporation.[18] [18] In the 1890s, the company launched its first nationally recognized product, Sal Hepatica, a laxative mineral salt, followed by Ipana toothpaste in 1901.

[19] [20] The other business units were Clairol (hair dyes and hair care) and Drackett (household products such as Windex and Drano). [21] Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients overcome serious diseases. Bristol Myers Squibb (BMS) is an American pharmaceutical company headquartered in New York City. [2] The strategic divestiture of the company`s consumer healthcare business, UPSA, to Taisho was completed in 2019. [67] UPSA focused product delivery on France and the rest of Europe. Already in 2005, the company had sold individual consumer goods,[68][69] and its consumer goods business focused on the United States and Canada. [70] In October 2010, the company acquired ZymoGenetics, thereby obtaining an existing product and portfolio assets in the areas of hepatitis C, cancer and other therapeutic areas. It offers products for hematological, oncological, cardiovascular, immunological, fibrotic, neuroscientific and Covid-19 diseases. The company`s products include Revlimid, an oral immunomodulatory drug used to treat multiple myeloma; Eliquis, an oral inhibitor to reduce the risk of systemic stroke/embolism in NVAF and to treat DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome positive chronic myeloid leukemia; Yervoy for the treatment of patients with inoperable or metastatic melanoma; Abraxane, a protein-related chemotherapy drug Reblozyl for the treatment of anemia in adult patients with beta-thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia for the treatment of recurrent forms of multiple sclerosis; Breyanzi, a genetically modified autologous T-cell immunotherapy directed by CD19 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML.

It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies. The company was previously known as the Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. In August 2009, BMS acquired the biotech company Medarex as part of a major restructuring activity as part of the alliance, partnership and acquisition company`s “String of Pearls” strategy. [52] In November 2009, Bristol Myers Squibb announced that it would “separate” from Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their shares for shares of Mead Johnson. [53] According to Bristol Myers Squibb, this decision should further strengthen the company`s focus on biopharmaceuticals. [53] In July 2006, an investigation into the company was published and the FBI raided the company`s offices. [36] The investigation focused on the spread of Plavix and the allegation of collusion. [36] [37] On September 12, 2006, the Monitor, former federal judge Frederick B.